These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27903098)

  • 1. Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept.
    Rodriguez CI; Zwerling J; Kalanthroff E; Shen H; Filippou M; Jo B; Simpson HB; Burch RM; Moskal JR
    Am J Psychiatry; 2016 Dec; 173(12):1239-1241. PubMed ID: 27903098
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Rapastinel (Formerly GLYX-13) on Serum Brain-Derived Neurotrophic Factor in Obsessive-Compulsive Disorder.
    Linkovski O; Shen H; Zwerling J; Filippou-Frye M; Jo B; Cordell E; Cooper TB; Simpson HB; Burch RM; Moskal JR; Lee F; Rodriguez CI
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505186
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
    Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
    J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
    Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
    Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats.
    Burgdorf J; Kroes RA; Zhang XL; Gross AL; Schmidt M; Weiss C; Disterhoft JF; Burch RM; Stanton PK; Moskal JR
    Behav Brain Res; 2015 Nov; 294():177-85. PubMed ID: 26210936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
    Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
    Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant.
    Moskal JR; Burgdorf JS; Stanton PK; Kroes RA; Disterhoft JF; Burch RM; Khan MA
    Curr Neuropharmacol; 2017; 15(1):47-56. PubMed ID: 26997507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder.
    Wilhelm S; Buhlmann U; Tolin DF; Meunier SA; Pearlson GD; Reese HE; Cannistraro P; Jenike MA; Rauch SL
    Am J Psychiatry; 2008 Mar; 165(3):335-41; quiz 409. PubMed ID: 18245177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the activity of
    Vasilescu AN; Schweinfurth N; Borgwardt S; Gass P; Lang UE; Inta D; Eckart S
    Neuropsychiatr Dis Treat; 2017; 13():973-980. PubMed ID: 28408831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion.
    Rodriguez CI; Levinson A; Zwerling J; Vermes D; Simpson HB
    J Clin Psychiatry; 2016 May; 77(5):688-9. PubMed ID: 27249077
    [No Abstract]   [Full Text] [Related]  

  • 12. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus.
    Burgdorf J; Zhang XL; Weiss C; Gross A; Boikess SR; Kroes RA; Khan MA; Burch RM; Rex CS; Disterhoft JF; Stanton PK; Moskal JR
    Neuroscience; 2015 Nov; 308():202-11. PubMed ID: 26343295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder.
    Albelda N; Bar-On N; Joel D
    Psychopharmacology (Berl); 2010 May; 210(1):13-24. PubMed ID: 20238210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study.
    Wu PL; Tang HS; Lane HY; Tsai CA; Tsai GE
    J Clin Psychopharmacol; 2011 Jun; 31(3):369-74. PubMed ID: 21508860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comorbid obsessive-compulsive personality disorder in obsessive-compulsive disorder (OCD): a marker of severity.
    Lochner C; Serebro P; van der Merwe L; Hemmings S; Kinnear C; Seedat S; Stein DJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1087-92. PubMed ID: 21411045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder.
    Uguz F
    Gen Hosp Psychiatry; 2010; 32(5):556-8. PubMed ID: 20851277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults.
    Grassi G; Pallanti S
    Expert Opin Pharmacother; 2018 Oct; 19(14):1541-1550. PubMed ID: 30321070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
    Sevincok L; Topuz A
    J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study.
    Arnold PD; Rosenberg DR; Mundo E; Tharmalingam S; Kennedy JL; Richter MA
    Psychopharmacology (Berl); 2004 Aug; 174(4):530-8. PubMed ID: 15083261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of Intensive Cognitive Behaviour Therapy in a Residential Setting for People with Severe Obsessive Compulsive Disorder: A Large Open Case Series.
    Veale D; Naismith I; Miles S; Childs G; Ball J; Muccio F; Darnley S
    Behav Cogn Psychother; 2016 May; 44(3):331-46. PubMed ID: 26122913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.